A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02566005 |
|
Recruitment Status :
Completed
First Posted : October 1, 2015
Results First Posted : March 27, 2018
Last Update Posted : March 27, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pregnancy | Device: misoprostol Device: Foley bulb | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 200 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Supportive Care |
| Official Title: | A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor |
| Study Start Date : | September 2015 |
| Actual Primary Completion Date : | July 2016 |
| Actual Study Completion Date : | July 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: misoprostol group
The women in the misoprostol only group will receive 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist
|
Device: misoprostol
25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
Other Name: cytotec |
|
Active Comparator: misoprostol and foley bulb group
Women in the combination group will receive vaginal misoprostol per standard protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter.
|
Device: misoprostol
25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
Other Name: cytotec Device: Foley bulb a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
Other Name: foley bulb (ballon) |
- The Time Interval From Induction to Delivery: All Participants [ Time Frame: Day 1 ]During labor from the start of the induction to the delivery
- Time (Hours) From Induction to Delivery: Nulliparous [ Time Frame: Day 1 ]
- Time (Hours) From Induction to Delivery: Multiparous [ Time Frame: Day 1 ]
- Time From Induction to Delivery: VD [ Time Frame: Day 1 ]Time (hours) from induction to delivery: Vaginal Delivery (VD)
- Time From Induction to Delivery: CD [ Time Frame: Day 1 ]Time (hours) from induction to delivery: Cesarean Delivery (CD)
- Per Treatment Protocol: Time (Hours) From Induction to Delivery [ Time Frame: day 1 ]
- The Time From Induction Until to Active Phase Labor [ Time Frame: Day 1 ]
- The Time From Active Phase to Delivery [ Time Frame: Day 1 ]
- Incidence of Chorioamnionitis [ Time Frame: Day 1 ]
- Incidence of Uterine Tachysystole [ Time Frame: Day 1 ]
- Incidence of Patient Discomfort [ Time Frame: Day 1 ]
- Estimated Blood Loss [ Time Frame: Day 1 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria
- Term 37 weeks or more, singleton in cephalic presentation
- Age 18 years and older
- Patient admitted for induction of labor
Exclusion Criteria:
- Malpresentation
- Preterm labor less than 37 weeks of gestation
- Patients with fetal anomalies
- Premature rupture of membranes
- If the cervix is closed and unable to place the foley bulb
- Multiple gestation
- Non-reassuring fetal heart tracing
- Contraindication to misoprostol
- Contraindication to vaginal delivery (i.e. placenta previa, vasa previa, active vaginal bleeding, marginal previa, macrosomia, etc). History of prior uterine surgery such as cesarean section or myomectomy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02566005
| United States, New York | |
| Mount Sinai Roosevelt | |
| New York, New York, United States, 10019 | |
| Principal Investigator: | Zainab Al-Ibraheemi, MD | Mount Sinai St Luke's Roosevelt Hospital |
| Responsible Party: | St. Luke's-Roosevelt Hospital Center |
| ClinicalTrials.gov Identifier: | NCT02566005 |
| Other Study ID Numbers: |
15-0032 |
| First Posted: | October 1, 2015 Key Record Dates |
| Results First Posted: | March 27, 2018 |
| Last Update Posted: | March 27, 2018 |
| Last Verified: | February 2018 |
|
Misoprostol Induction Foley |
|
Misoprostol Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents |
Physiological Effects of Drugs Anti-Ulcer Agents Gastrointestinal Agents Oxytocics |

